Skip Navigation

Masks are required inside all of our care facilities. We are vaccinating all eligible patients. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Email Alerts

Find more COVID-19 testing locations on Maryland.gov.

Brain Tumor Clinical Trials

Clinical trials help bring hope, advance treatments, and often improve prognosis. Trials can be especially helpful for patients who have had a tumor come back, and the tumor is known to be aggressive and not responsive to current treatments.

Clinical trials are scientific studies in which new treatments are tested in patients to determine if they are safe and effective. Johns Hopkins has a long history of collaboration between basic scientists and clinical scientists, who advance new ideas from the laboratory to patients. We believe that well-designed and carefully conducted research will lead us to the next major breakthrough in the treatment of patients with malignant brain tumors.

To qualify for a clinical trial, participants must meet carefully defined criteria. Please contact the study nurse for the trial you are interested in to see if you qualify and if there are open spots in the trial. You may also reach out to our study nurses if you are unsure which trial is right for you:

 

Trials for Patients Who've Been Diagnosed with a Brain Tumor for the First Time

Study of Subventricular Zone (SVZ) Irradiation+TMZ in New Glioblastoma (IRB00031466, J1426)

Contact: Kristin Redmond, MD (410-614-1642 or kjanson3@jhmi.edu) or Jacqueline Quivers (202-243-2294, jquiver1@jhmi.edu for Sibley location)
Principal Investigator: Dr. Kristin Redmond
Objective: To see if an investigational method of giving radiation to adults with glioblastoma multiforme (GBM) can improve the local control and increase the time it may take for your brain cancer from coming back.
Eligibility Criteria: Adults with glioblastoma (GBM)
More information on clinicaltrials.gov: NCT02177578

Study of Radiotherapy with Temozololide vs Radiotherapy with PCV Chemotherapy Anaplastic Glioma or Low-Grade Glioma (NCTNA0577, NA_00093264)

Contact: Phase1 Clinical Trials (JHCTN@jhmi.edu) and Jeannette Smith (jsmith@jhmi.edu)
Principal Investigator: Dr. Matthias Holdhoff
Objective: To compare standard chemoradiation with radiotherapy followed by PCV chemotherapy [PCV chemotherapy consists of three drugs, Matulane (procarbazine), Lomustine (CCNU) and Oncovin (vincristine)] in of anaplastic glioma or low-grade glioma
Eligibility Criteria: Adults with Anaplastic Glioma or Low Grade Glioma with the 1p/19q co-deletion and IDH tumor markers
More information on clinicaltrials.gov: NCT00887146

Study of Optune® (TTFields) with radiation therapy and temozolomide for newly diagnosed glioblastoma (IRB00283089, J2144)

Contact: Kelly Szajna, RN, BSN (410-502-4081 or kszajna1@jhmi.edu)
Principal Investigator: Dr. Lawrence Kleinberg
Objective: The purpose of this study is to determine whether using Optune® (a tumor-treating fields device) during radiation therapy in the treatment of newly-diagnosed glioblastoma multiforme (GBM) improves survival when compared to starting Optune® following the completion of radiation therapy.
Eligibility Criteria: Adults with newly diagnosed GBM who have undergone surgery or biopsy and are planning to receive radiation therapy (RT) with concomitant temozolomide (TMZ)
More information on clinicaltrials.gov: NCT04471844

Trials for Patients Whose Brain Tumor Returned After Treatment

Trial of Immunotherapy and Stereotactic Radiosurgery in Recurrent GBM (IRB00104226, J18150)

Contact: Kelly Szajna, RN, BSN (410-502-4081 or kszajna1@jhmi.edu)
Principal Investigator: Dr. Lawrence Kleinberg
Objective: To find out if two study drugs PDR001 and MBG453 are safe to give with stereotactic radiosurgery (SRS).
Eligibility Criteria: Adults with recurrent glioblastoma (GBM)
More information on clinicaltrials.gov: NCT03961971

Study of RAF and MEK inhibitors in BRAF-V600E mutated recurrent gliomas (IRB00158788, J1801)

Contact: Dr. Karisa Schreck, MD (ksolt1@jhmi.edu)
Principal Investigator: Dr. Karisa Schreck
Objective: To find out how well encorafenib and binimetinib work in treating recurrent high-grade primary brain tumors.
Eligibility Criteria: Adults with high-grade tumors with BRAF-V600 E or K mutation
More information on clinicaltrials.gov: NCT03593993

Study of SMO/AKT/NF2CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations/CDK Pathway Mutations (IRB00102683, NCTNA071401)

Contact: Phase 1 Clinical Trials (JHCTN@jhmi.edu) and Jeannette Smith (jsmith@jhmi.edu) or Jacqueline Quivers (202-243-2294 or jquiver1@jhmi.edu for Sibley location)
Principal Investigator: Dr. Chetan Bettegowda
Objective: To test good and bad effects of these four different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients, and is not based on tumor genetic testing.
Eligibility Criteria: Adults with meningioma which has gotten bigger or grew back after treatment.
More information on clinicaltrials.gov: NCT02523014

Trials for Other Central Nervous System Tumors

Stereotactic Radiosurgery with Nivolumab in Subjects with Chordoma (IRB00117650)

Contact: Kelly Szajna (410-502-4081 or kszajna1@jhmi.edu)
Principal Investigator: Dr. Lawrence Kleinberg
Objective: To look at the safety of using Nivolumab alone or Nivolumab and stereotactic radiosurgery (SRS) together to treat advanced chordomas.
Eligibility Criteria: Advanced/recurrent chordoma in 1 or more sites
More information on clinicaltrials.gov: NCT02989636

Observational Studies and Supportive Care

Unlike clinical trials, observational studies are designed to observe rather than treat. In an observational study, researchers may evaluate changes in symptoms, results or side effects of a treatment, or how well different diagnostic methods detect or monitor brain tumors. For example, researchers may ask observational study participants to undergo an imaging test, such as MRI or PET scan to learn about diagnosing brain tumors from imaging. Both patients with brain tumors and healthy volunteers can participate in observational studies.

Helping Enable Real-Time Observations (HERO): A brain tumor surveillance study (IRB00253818, J2099)

Contact: Kelly Szajna, RN, BSN (410-502-4081 or kszajna1@jhmi.edu)
Principal Investigator: Dr. Chetan Bettegowda
Objective: To see if the information collected from wearable devices can be used to detect changes in symptoms for patients with brain tumors.
Eligibility Criteria: Adults with high grade brain cancer

Non-invasive measurement of chemotherapy drug concentration using chemical exchange saturation transfer MRI – a feasibility study (IRB00237563, J2029)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principle and Co-Investigator: Dr. David Kamson and Dr. Stuart Grossman
Objective: To assess the feasibility to non-invasively detect and quantify chemotherapy drug concentrations in vivo using a label-free MRI method.
Eligibility Criteria: Patients with tumors treated with high-dose methotrexate chemotherapy

Protein and metabolite mapping of human muscle and brain by MRI  (IRB00283785)

Contact: Contact: Jiadi Xu (410-598-0920 or jxu37@jh.edu)
Principal Investigator: Jiadi Xu
Objective: To examine the protein profile and metabolites changes after the chemotherapy using a non-invasive MRI method.
Eligibility Criteria: Healthy volunteers ages 18-80
More information on clinicaltrials.gov: NCT04234880

Human brain protein MR imaging and spectroscopy (NA_00034512, J0578)

Contact: Lindsay Blair (lblair1@jhmi.edu)
Principle and Co-Investigator: Jinyuan Zhou / Shanshan Jiang
Objective: To develop and refine a novel protein-based MRI technique, called amide proton transfer (APT) imaging, to better assess the status of disease in patients with brain tumors.
Eligibility Criteria: Known or suspected primary malignant brain tumors and healthy volunteers

Resource for quantitative functional MRI (IRB00036313)

Contact: Georg Oeltzschner (goeltzs1@jhmi.edu) and Lindsay Blair (lblair1@jhmi.edu)
Principle and Co-Investigator: Georg Oeltzschner
Objective: To develop and evaluate advanced spectral-edited magnetic resonance spectroscopic biomarkers of IDH and 1p/19q codelection in brain tumors

Development and translation of D-glucose as a diagnostic agent for MRI of cancer (NA_00049677)

Contact: Nirbhay Yadav (nyadav@jhu.edu) or Lindsay Blair (lblair1@jhmi.edu)
Principle and Co-Investigator: Peter van Zijl / Nirbhay Yadav
Objective: To develop and translate to the clinic the use of D-glucose as an intravenous MRI contrast agent for the combined imaging of tumor perfusion, permeability, and metabolism.
Eligibility Criteria: Brain mass consistent with a primary brain tumor or metastatic brain tumor and healthy volunteers

Browse other clinical trials

For a complete list of open clinical trials across Johns Hopkins, visit the database at the Institute for Clinical and Translational Research. You can search by condition, researcher or doctor’s name.

back to top button